Though the full effects of G9a are still under investigation, there are abundant resources to direct future research on G9a interactions with other epigenetic regulators, through inhibition studies, RNA interference, CRISPR knockouts, and mouse models, while taking into account the broader impact of G9a inhibition on tumor-associated fibroblasts and the immune components of the microenvironment. The gene discussed is EHMT2; the disease is neoplasm.